Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 09/23 05:35:13 pm
1653 GBp   +0.24%
09/23DJGLAXOSMITHKLINE : Files US Regulatory Application for Sirukumab in R..
09/23 GLAXOSMITHKLINE : GSK announces US regulatory submission for sirukum..
09/23 GLAXOSMITHKLINE : Files Licence Application For Arthritis Treatment
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
09/23DJGLAXOSMITHKLINE : Files US Regulatory Application for Sirukumab in Rheumatoid Ar..
09/23 GLAXOSMITHKLINE : GSK announces US regulatory submission for sirukumab in rheuma..
09/23 GLAXOSMITHKLINE : Files Licence Application For Arthritis Treatment
09/23 GLAXOSMITHKLINE : US Regulatory Submission for sirukumab in RA
09/23DJGLAXOSMITHKLINE : GSK Submits for Subcutaneous Formulation of Benlysta in US, Eu..
09/23 GLAXOSMITHKLINE : Glaxo Files US, European Submissions For Benlysta In Systemic ..
09/23 GLAXOSMITHKLINE : GSK announces regulatory submissions for subcutaneous formulat..
09/21 Emma named as new Glaxo
09/21 Emma named as new Glaxo chief
09/21DJGLAXOSMITHKLINE : Glaxo Taps Consumer Chief -- WSJ
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 Janssen submits marketing application in U.S. for sirukumab for rheumatoid ar..
09/22 Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth
09/20 Gilead Will Take Out $80 Any Day Now
09/20 WALL STREET BREAKFAST : Fed, BOJ Meetings Begin
Advertisement
Financials ( GBP)
Sales 2016 26 978 M
EBIT 2016 7 126 M
Net income 2016 2 684 M
Debt 2016 13 482 M
Yield 2016 4,85%
P/E ratio 2016 35,93
P/E ratio 2017 21,59
EV / Sales 2016 3,49x
EV / Sales 2017 3,31x
Capitalization 80 593 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 17,5  GBP
Spread / Average Target 5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Moncef Slaoui Executive Director & Chairman-Global Vaccines
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC20.39%104 476
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results